Patient P-01627

Synthetic patientNBL-101 · Day 114 · 35–44 · M · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Deteriorating

GI state

Improving

Inflammatory state

Improving

Nutritional resilience

Improving

Discontinuation risk

60%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 56 GI-04 recommended — GI Support Protocol GI-04
Day 57 Patient accepted — Started GI-04 in the companion
Day 65 GI symptom burden −30% vs expected — GI Support Protocol GI-04
Day 71 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

GI instability-21
Nutritional resilience+19
Inflammatory activity-9
Toxicity+9
Treatment adherence+7

What helped?

GI Support Protocol GI-04Day 56
Result: symptom burden −30%

LIFE OS recommendation

Dietary Support Protocol NP-02

54%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 53
- WearableHRV 28 ms, trending down
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 46 and rising
- WearableSleep 5.7 h, below personal baseline
Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 39/100
- MicrobiomeF. prausnitzii depleted
Drug metabolism and exposure ↑20
- BloodToxicity index 47
Autonomic recovery ↓20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.7 · butyrate capacity 39/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 5.9 h
Steps: 5,085
Resting HR: 74 bpm

Daily log: GI score 46, nutritional resilience 51, adherence 58.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01706	62%	S14	GI-04	improved	55
P-01624	58%	S14	GI-04	improved	52
P-01438	57%	S14	GI-04	improved	56
P-01879	57%	S14	SC-12	improved	51
P-01556	54%	S14	GI-04	improved	44
P-01323	52%	S14	GI-04	improved	50
P-01365	51%	S14	SC-12	improved	49
P-01400	51%	S17	GI-04	improved	51
P-01393	50%	S14	GI-04	improved	53
P-01473	50%	S14	GI-04	improved	51
P-01543	50%	S14	GI-04	improved	54
P-01573	50%	S14	GI-04	improved	49